Survival analysis in overall older advanced NSCLC patients
The median follow-up time from
EGFR-TKI treatment initiation was
19.4 months. The median PFS of all older advanced NSCLC patients treated
with immune checkpoint inhibitors (ICIs) was 12.6 months (95% CI =
10.7–14.7), and the median OS time was 24.5 months (95% CI =
20.3–27.7).
Survival analysis in PP(+) and PP(–) older advanced NSCLC